Okuma Y - Search Results

1

A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors.

Shaikh FY, White JR, Gills JJ, Hakozaki T, Richard C, Routy B, Okuma Y, Usyk M, Pandey A, Weber JS, Ahn J, Lipson EJ, Naidoo J, Pardoll DM, Sears CL. Shaikh FY, et al. Among authors: okuma y. Clin Cancer Res. 2021 May 1;27(9):2571-2583. doi: 10.1158/1078-0432.CCR-20-4834. Epub 2021 Feb 16. Clin Cancer Res. 2021. PMID: 33593881 Free PMC article.

2

Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients.

Mitsuhashi A, Okuma Y. Mitsuhashi A, et al. Among authors: okuma y. Clin Transl Oncol. 2018 Aug;20(8):966-974. doi: 10.1007/s12094-017-1827-7. Epub 2018 Jan 8. Clin Transl Oncol. 2018. PMID: 29313208 Review.

3

Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report.

Hakozaki T, Okuma Y, Kashima J. Hakozaki T, et al. Among authors: okuma y. BMC Cancer. 2018 Mar 20;18(1):302. doi: 10.1186/s12885-018-4212-1. BMC Cancer. 2018. PMID: 29554874 Free PMC article.

4

Statins improve survival in patients previously treated with nivolumab for advanced non-small cell lung cancer: An observational study.

Omori M, Okuma Y, Hakozaki T, Hosomi Y. Omori M, et al. Among authors: okuma y. Mol Clin Oncol. 2019 Jan;10(1):137-143. doi: 10.3892/mco.2018.1765. Epub 2018 Nov 13. Mol Clin Oncol. 2019. PMID: 30655989 Free PMC article.

5

Impact of prior antibiotic use on the efficacy of nivolumab for non-small cell lung cancer.

Hakozaki T, Okuma Y, Omori M, Hosomi Y. Hakozaki T, et al. Among authors: okuma y. Oncol Lett. 2019 Mar;17(3):2946-2952. doi: 10.3892/ol.2019.9899. Epub 2019 Jan 8. Oncol Lett. 2019. PMID: 30854072 Free PMC article.

6

Radiographic Assessment of Objective Responses Using the ITMIG-Modified Criteria in Thymic Carcinoma.

Hakozaki T, Okuma Y, Hosomi Y, Hishima T. Hakozaki T, et al. Among authors: okuma y. Oncology. 2019;97(5):264-269. doi: 10.1159/000501104. Epub 2019 Jul 15. Oncology. 2019. PMID: 31307031

7

Correlation between the qualification for bevacizumab use and the survival of patients with non-small cell lung cancer harboring the epidermal growth factor receptor mutation: a retrospective analysis.

Hakozaki T, Okuma Y, Hashimoto K, Hosomi Y. Hakozaki T, et al. Among authors: okuma y. J Cancer Res Clin Oncol. 2019 Oct;145(10):2555-2564. doi: 10.1007/s00432-019-02985-1. Epub 2019 Jul 26. J Cancer Res Clin Oncol. 2019. PMID: 31350622

8

Management of non-small cell lung cancer harboring epidermal growth factor receptor mutations in the era of first-line osimertinib.

Hakozaki T, Okuma Y. Hakozaki T, et al. Among authors: okuma y. J Thorac Dis. 2019 Jul;11(7):2664-2668. doi: 10.21037/jtd.2019.06.16. J Thorac Dis. 2019. PMID: 31463088 Free PMC article. No abstract available.

9

The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases.

Kitadai R, Okuma Y, Hakozaki T, Hosomi Y. Kitadai R, et al. Among authors: okuma y. J Cancer Res Clin Oncol. 2020 Mar;146(3):777-785. doi: 10.1007/s00432-019-03104-w. Epub 2019 Dec 11. J Cancer Res Clin Oncol. 2020. PMID: 31828427

10

Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer.

Hakozaki T, Hosomi Y, Kitadai R, Kitagawa S, Okuma Y. Hakozaki T, et al. Among authors: okuma y. J Cancer Res Clin Oncol. 2020 Nov;146(11):2957-2966. doi: 10.1007/s00432-020-03271-1. Epub 2020 May 27. J Cancer Res Clin Oncol. 2020. PMID: 32462297

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

573 results

Search Page

Filters